COVID-19与ICU获得性多重耐药菌定植和感染的关系:一项前瞻性多中心前后对照研究
该研究为法国7个ICU的前瞻性前后对照研究,纳入367例ICU停留>48小时且确诊SARS-CoV-2感染的患者,随访28天,与同一ICU近期前瞻性队列的680例对照比较。入ICU时及此后每周系统筛查多重耐药(MDR)细菌定植。主要终点为ICU获得性MDR细菌定植和/或感染(ICU-MDR-col和/或ICU-MDR-inf)的累积发生率。校正预设基线混杂因素后,复合终点两组差异未达统计学显著(校正sHR 1.39,95%CI 0.91-2.09);分开分析时,COVID-19组ICU-MDR-inf发生率高于对照(校正sHR 2.50,95%CI 1.90-3.28),而ICU-MDR-col两组差异未达统计学显著(校正sHR 1.27,95%CI 0.85-1.88)。
要点
- COVID-19患者ICU获得性MDR细菌感染发生率高于对照(校正sHR 2.50,95%CI 1.90-3.28)。
- 复合终点ICU-MDR-col和/或ICU-MDR-inf两组差异未达统计学显著(校正sHR 1.39,95%CI 0.91-2.09)。
- COVID-19组与对照的ICU-MDR-col发生率差异未达统计学显著(校正sHR 1.27,95%CI 0.85-1.88)。
- 研究在法国7个ICU进行,纳入ICU停留>48小时且确诊SARS-CoV-2感染的患者367例,对照680例,随访28天。
- 入ICU时及此后每周系统筛查MDR细菌定植。
适用人群与场景
- 法国7个ICU中ICU停留>48小时且确诊SARS-CoV-2感染、连续前瞻性纳入并随访28天的患者(367例),对照为同一ICU近期前瞻性队列的680例患者。
研究设计与关键结果
- 研究类型:前瞻性多中心前后对照观察性研究,法国7个ICU,2020年2月27日至2021年6月2日纳入367例COVID-19患者,对照680例。
- 主要终点:校正预设基线混杂因素后,ICU-MDR-col和/或ICU-MDR-inf复合终点累积发生率两组差异未达统计学显著(校正sHR 1.39,95%CI 0.91-2.09)。
- 次要终点:COVID-19组ICU-MDR-inf发生率高于对照(校正sHR 2.50,95%CI 1.90-3.28);ICU-MDR-col两组差异未达统计学显著(校正sHR 1.27,95%CI 0.85-1.88)。
证据类型、等级与局限
- 证据类型:前瞻性多中心前后对照观察性研究。
- 局限:原文未报告局限性
对床旁实践的改变
- 原文结论:COVID-19患者ICU-MDR-inf发生率高于对照,但复合终点(ICU-MDR-col和/或ICU-MDR-inf)差异未达统计学显著。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Patients presenting the most severe form of coronavirus disease 2019 (COVID-19) pneumonia, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have a prolonged intensive care unit (ICU) stay and are exposed to broad-spectrum antibiotics, but the impact of COVID-19 on antimicrobial resistance is unknown.
METHODS: Observational prospective before-after study in 7 ICUs in France. All consecutive patients with an ICU stay > 48 h and a confirmed SARS-CoV-2 infection were included prospectively and followed for 28 days. Patients underwent systematic screening for colonization with multidrug-resistant (MDR) bacteria upon admission and every week subsequently. COVID-19 patients were compared to a recent prospective cohort of control patients from the same ICUs. The primary objective was to investigate the association of COVID-19 with the cumulative incidence of a composite outcome including ICU-acquired colonization and/or infection related to MDR bacteria (ICU-MDR-col and ICU-MDR-inf, respectively).
RESULTS: From February 27th, 2020 to June 2nd, 2021, 367 COVID-19 patients were included, and compared to 680 controls. After adjustment for prespecified baseline confounders, the cumulative incidence of ICU-MDR-col and/or ICU-MDR-inf was not significantly different between groups (adjusted sub-hazard ratio [sHR] 1.39, 95% confidence interval [CI] 0.91-2.09). When considering both outcomes separately, COVID-19 patients had a higher incidence of ICU-MDR-inf than controls (adjusted sHR 2.50, 95% CI 1.90-3.28), but the incidence of ICU-MDR-col was not significantly different between groups (adjusted sHR 1.27, 95% CI 0.85-1.88).
CONCLUSION: COVID-19 patients had an increased incidence of ICU-MDR-inf compared to controls, but the difference was not significant when considering a composite outcome including ICU-MDR-col and/or ICU-MDR-inf.
参考来源
- Kreitmann L, Jermoumi S, Vasseur M, et al. Relationship between COVID-19 and ICU-acquired colonization and infection related to multidrug-resistant bacteria: a prospective multicenter before-after study. Intensive Care Med. 2023. PMID: 37326645. doi:10.1007/s00134-023-07109-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。